- Home
- ALX vs NVAX Comparison
ALX vs NVAX Comparison
Compare ALX & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALX
- NVAX
- Stock Information
- Founded
- ALX 1928
- NVAX 1987
- Country
- ALX United States
- NVAX United States
- Employees
- ALX N/A
- NVAX N/A
- Industry
- ALX Real Estate Investment Trusts
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALX Real Estate
- NVAX Health Care
- Exchange
- ALX Nasdaq
- NVAX Nasdaq
- Market Cap
- ALX 1.2B
- NVAX 1.3B
- IPO Year
- ALX N/A
- NVAX 1995
- Fundamental
- Price
- ALX $234.35
- NVAX $7.90
- Analyst Decision
- ALX
- NVAX Buy
- Analyst Count
- ALX 0
- NVAX 7
- Target Price
- ALX N/A
- NVAX $14.29
- AVG Volume (30 Days)
- ALX 42.7K
- NVAX 7.9M
- Earning Date
- ALX 11-03-2025
- NVAX 08-06-2025
- Dividend Yield
- ALX 7.75%
- NVAX N/A
- EPS Growth
- ALX N/A
- NVAX N/A
- EPS
- ALX 7.28
- NVAX 2.54
- Revenue
- ALX $218,089,000.00
- NVAX $1,078,718,000.00
- Revenue This Year
- ALX N/A
- NVAX $61.69
- Revenue Next Year
- ALX N/A
- NVAX N/A
- P/E Ratio
- ALX $31.61
- NVAX $3.10
- Revenue Growth
- ALX N/A
- NVAX 9.22
- 52 Week Low
- ALX $184.76
- NVAX $5.01
- 52 Week High
- ALX $260.84
- NVAX $15.22
- Technical
- Relative Strength Index (RSI)
- ALX 55.16
- NVAX 51.27
- Support Level
- ALX $226.28
- NVAX $7.23
- Resistance Level
- ALX $236.57
- NVAX $10.64
- Average True Range (ATR)
- ALX 4.68
- NVAX 0.46
- MACD
- ALX 1.10
- NVAX -0.10
- Stochastic Oscillator
- ALX 87.54
- NVAX 19.65
About ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing and redeveloping its properties. It has six properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.